The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET/MR identify systemic amyloid deposits across clinically and histologically defined patient groups?
Participants will:
* Be screened for eligibility and asked to sign an informed consent form
* Have their vital signs measured
* Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET/MR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET/CT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner
* Be monitored during and after the scan for any side effects or adverse events
* Complete study participation at the end of the imaging session (single visit, no follow-up required)

开始日期2026-10-01

申办/合作机构

University of Zurich

NCT07169630

/ Recruiting临床1期IIT

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)

Background:
About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.
Objective:
To test whether medical imaging using a new radiotracer ([18F]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.
Eligibility:
People aged 50 years and older with AD or MCI. Healthy volunteers are also needed.
Design:
Participants will have up to 5 clinic visits with 3 imaging scans of the brain.
They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.
Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.
Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....

开始日期2026-08-26

申办/合作机构

National Institute of Mental Health

NCT07758660

/ Enrolling by invitation临床2期IIT

Alzheimer's Disease Research Center PET Component

The purpose of this study is to further engage and characterize Alzheimer's Disease Research Center (ADRC) participants through additional research opportunities, particularly PET imaging. Amyloid and Tau PET imaging will be collected in 24 participants per year, for a total of 120 participants over five years.
All participants will be followed longitudinally, including through potential transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD).

开始日期2026-08-06

申办/合作机构

Columbia University

[+1]

100 项与氟[¹⁸F]贝他苯相关的临床结果

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的转化医学

登录后查看更多信息

100 项与氟[¹⁸F]贝他苯相关的专利（医药）

登录后查看更多信息

217

项与氟[¹⁸F]贝他苯相关的文献（医药）

2026-05-01·JPAD-Journal of Prevention of Alzheimers Disease

Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake

Article

作者: Devanarayan, Viswanath ; Charil, Arnaud ; Reyderman, Larisa ; Kramer, Lynn D ; Irizarry, Michael C ; Reilhac, Anthonin ; Dhadda, Shobha ; Nelson, Todd M

BACKGROUND:

The visual interpretation of amyloid PET scans, or visual read (VR), is the most common technique used in clinical practice to identify the presence of cerebral amyloid plaques. Amyloid status (positive or negative) determined by VR or using a Centiloid (CL) cut-off shows high overall concordance. However, discordant cases can occur where the VR is positive, but the CL is below the positivity cut-off, or vice versa.

OBJECTIVES:

The objective of this analysis was to evaluate the rate of discordance and explore potential causes, particularly the role of amyloid tracer uptake in the white matter (WM), when determining amyloid status using VR and CL in screening for the elenbecestat phase 3 studies in early Alzheimer's disease (AD).

DESIGN:

Amyloid PET scans using either Florbetapir (Amyvid™), Florbetaben (Neuraceq™) or Flutemetamol (Vizamyl™) from 3,232 participants (1507 VR- and 1725 VR+) with cognitive impairment screened for the elenbecestat phase 3 studies in early AD were visually interpreted at screening by trained neuroradiologists and quantified using CL values.

SETTING:

Academic and clinical centers INTERVENTION/MEASUREMENTS: Quantitatively, amyloid positivity was defined as CL > 32.21. The number of positive cortical regions was determined by counting the number of regions with a standardized uptake value ratio (SUVr) that exceeded 1.17. PET SUVr levels in the cerebral WM were measured using an eroded WM region of interest (ROI). Statistical tests were conducted to detect differences among the four concordance groups, defined by the relationship of VR and CL status (positive or negative). Additionally, tests examined the relationship between uptake in the WM and rates and type of discordance. Receiver operating characteristic (ROC) analysis and DeLong's test were also used to examine the effect of different tracers on the discordant rates.

RESULT:

Discordance was observed in 6.53% of cases (n=211), with VR+/CL- in 4.61% (n=149) and VR-/CL+ in 1.92% (n=62). VR+/CL- discordant cases had significantly fewer amyloid-positive cortical regions compared to both VR+/CL+ and VR-/CL+ cases. VR-/CL+ cases had a significantly higher WM uptake than VR-/CL- and VR+/CL- cases. Our findings revealed a relationship between WM uptake and rates and types of discordance. High WM uptake can erroneously lead to CL+, due to gray matter (GM) contamination from the WM, and VR- status, due to reduced contrast between WM and GM, resulting in VR-/CL+ cases. Conversely, low WM uptake can result in an underestimation of CL values, inaccurately classifying a scan as CL-, and at the same time, the increased contrast may result in a VR+, thereby increasing the occurrence of discordant VR+/CL- cases.

CONCLUSION:

Variations in WM uptake significantly contribute to discordances by introducing positive or negative bias in CL values and altering the GM to WM contrast, which forms the basis of the VR. Nevertheless, the rates of discordant cases are low and VR represents a robust and validated method to determine the presence of amyloid deposition. VR enables enrolling patients with amyloid beta pathology, as seen on amyloid PET scans, whereas CL scaling was developed to provide standardized units that more consistently characterize longitudinal amyloid‑β change. These findings reflect the complementary roles of VR and CL in amyloid PET evaluation, with implications for refining diagnostic accuracy and disease monitoring in AD clinical trials and practice.

2026-05-01·JOURNAL OF NUCLEAR CARDIOLOGY

An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis

Review

作者: Martin, Emily B ; Wall, Jonathan S

Cardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by advances in transthyretin (TTR) stabilization and gene silencing, and immunotherapy to control monoclonal light chain production. Noninvasive diagnosis of transthyretin cardiac amyloidosis (ATTR) using technetium-99m bone-avid scintigraphy is now routine, yet these tracers do not bind amyloid and offer limited amyloid specificity, quantification, or monitoring of response to therapy. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) agents that directly engage amyloid or key downstream processes (fibroblast activation, inflammation, denervation) may redefine the diagnostic algorithm, phenotyping, risk stratification, and longitudinal assessment. Among these, iodine [¹²⁴I]evuzamitide (AT-01), a radioiodinated, pan-amyloid-binding peptide targeting amyloid fibrils and amyloid associated heparan sulfate proteoglycans, has emerged as the first amyloid-specific PET radiotracer to receive U.S. FDA Breakthrough Therapy designation for CA and has completed a Phase 3 pivotal evaluation. [¹⁸F]Florbetaben is similarly poised in a pivotal Phase 3 study. Herein, we summarize 1) Emerging radiotracers primed for clinical availability, including the pan-amyloid peptide tracers, [¹²⁴I]evuzamitide and [^99mTc]p5+14, the stilbene-based small molecule [¹⁸F]florbetaben, and the protein-based radiotracer, [^99mTc]aprotinin; 2) Research-focused, Aβ amyloid radiotracers and their performance in CA ([¹¹C]PiB; [¹⁸F]florbetapir, [¹⁸F]flutemetamol; and newer [¹⁸F]florbetazine); and 3) Adjunct radiotracers for exploring myocardial microenvironment ([⁶⁸Ga]FAPI, and others), emphasizing rationale for use, opportunities, synergies, strengths, limitations, and regulatory status. Finally, we outline future research and molecular targets to elucidate the pathology and the impact of novel amyloid therapeutics as they become available.

2026-03-01·Journal of Nuclear Medicine Technology

Quantitative Amyloid Brain Imaging: A Literature Review of the Centiloid Scale in Alzheimer Disease Evaluation

Review

作者: York, Benjamin ; Doroudinia, Abtin ; Colletti, Patrick M

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements across tracers, scanners, and analysis methods has considerably limited direct comparison of amyloid burden between studies and centers. To address this issue, the Centiloid Project has been developed to provide a standardized quantitative scale for amyloid PET, harmonizing results across tracers and institutions. In this literature review, we aim to summarize current evidence on the development, validation, and clinical application of the Centiloid scale in amyloid PET imaging, emphasizing its methodologic foundations, tracer-specific conversions, and diagnostic thresholds. Methods: A literature review was conducted using PubMed, Scopus, and Embase databases from January 2015 through October 2025. Search terms included "amyloid PET," "Centiloid," "SUVR," and "Alzheimer disease." We reviewed articles with quantitative amyloid PET analyses and Centiloid conversion and studies which compared multiple tracers using MIMneuro software Centiloid calibration. Results: The Centiloid method demonstrates strong intertracer and interscanner harmonization when standardized to the ¹¹C-Pittsburgh compound B reference, with high correlation (r ² > 0.9) across ¹⁸F-labeled tracers, including florbetapir, flutemetamol, and florbetaben. Most articles identified a Centiloid threshold between 20 and 25 Centiloids as indicative of significant amyloid pathology. Implementation of the Centiloid framework improved comparability across clinical trials and longitudinal studies, facilitating integration into the AT(N) research framework. Conclusion: The Centiloid scale represents a critical advancement in quantitative amyloid PET imaging, providing a universal reference that enhances data reproducibility, cross-trial comparisons, and clinical decision-making. Continued work is needed to expand standardization for novel tracers and hybrid imaging systems, ensuring full clinical translation of this metric in dementia imaging.

120

项与氟[¹⁸F]贝他苯相关的新闻（医药）

2026-08-18

·PRNewswire

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

COVINGTON, Ky., Aug. 18, 2026 /PRNewswire/ -- NeuroQuant ® PET has received FDA 510(k) clearance (K261916) for PET. NeuroQuant PET ® aids physicians in the evaluation of patient pathologies and the clinical interpretation of PET performed for the assessment of cognitive impairment and other neurological conditions. Continue Reading NeuroQuant ® PET by Cortechs.ai has received FDA 510(k) clearance (K261916) for PET. As molecular imaging plays an increasingly central role in the diagnosis and management of Alzheimer's disease and related neurodegenerative disorders, the demand for standardized, objective PET analysis continues to grow. NeuroQuant® PET is designed to deliver fully automated quantification, regional analysis, and structured reporting directly into routine clinical workflows. "Automated quantitative PET imaging represents the next frontier in precision and personalized medicine for Alzheimer's disease and related neurocognitive disorders. These new technological advancements are enabling the shift from phenotype-based assessment to a biological, biomarker-driven approach in assessing neurodegenerative disease. I am excited about the role NeuroQuant PET will play in shaping the future of how these conditions are understood and managed." said Dr. Ana Franceschi, M.D., Ph.D. The platform provides atlas-based quantification for amyloid PET tracers, generating standardized uptake value ratios (SUVRs) and structured reports to support consistent, data-driven interpretation. NeuroQuant® PET segments regions of interest and quantifies Centiloids for commonly used amyloid PET tracers flutemetamol, florbetaben, and florbetapir, enabling standardized comparison across tracers and imaging systems. Compatible with PET-CT, PET-MR, and PET-only workflows, NeuroQuant® PET features fully automated processing and PACS-ready outputs designed to integrate quantitative metrics into existing workflows. "NeuroQuant® PET reflects our commitment to advancing quantitative imaging in dementia care, giving clinicians objective, reproducible measurements they can trust, so patients get earlier answers and more confident treatment decisions" said Kyle Frye, CEO of Cortechs.ai. "With FDA 510(k)-clearance status, we look forward to expanding access to standardized PET quantification that supports precision medicine in Alzheimer's disease and related dementias." About Cortechs.ai Cortechs.ai is the leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and timely assessment, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical imaging solution software for assessing neurological disorders such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, tumors and prostate cancer, helping clinicians identify and monitor clinically significant cases. Cortechs.ai's industry-leading imaging solutions offer radiologists, oncologists, and urologists streamlined, cost-effective tools to assist in the assessment of brain and prostate health, including cancer evaluation. Visit  for additional insights and follow us on Twitter, LinkedIn, and Facebook. For more information, please contact: [email protected] +1 858 459 9700 SOURCE Cortechs.ai 21% more press release views with Request a Demo

2026-08-15

·温老李Eason

Alzheimer病：1906年图宾根的那个"51岁病例"

神经内科疾病·人名冠名系列 · 第4期 Alzheimer病：1906年图宾根的那个"51岁病例" 2026-08-03 · 阅读约 12 分钟 · 作者：Eason 门诊来了一个72岁的退休教师。家人说三年前开始忘记关煤气灶，最近一年出门找不到回家的路，把女儿叫成已故姐姐的名字。今早问他早餐吃了什么——想了很久，说"没吃"。其实吃了。 Alzheimer病——全球约5500万痴呆患者中占60-70%。中国60岁以上人群约1500万痴呆患者，其中AD约1000万。每3秒世界上就新增一位痴呆患者。史料出处 1. Alzheimer A. Über einen eigenartigen schweren Erkrankungsprozeß der Hirnrinde. Allg Z Psychiat. 1907;64:146-148. 2. Kraepelin E. Lehrbuch der Psychiatrie. 8th ed. Leipzig: Barth; 1910. 3. Jack CR Jr, et al. Revised criteria for diagnosis and staging of Alzheimer's disease. Alzheimers Dement. 2024;20(8):5143-5169. 发现史：图宾根精神病学年会上的6页讲稿 1906年11月3日，德国图宾根，第37届德国西南精神病学家年会。慕尼黑大学精神病诊所的Alois Alzheimer医生做了一个不到一小时的报告——病例名叫Auguste Deter。 Auguste Deter，1850年生，1901年（51岁）开始出现记忆衰退、妄想（怀疑丈夫不忠）、行为异常（藏东西、迷路）。1901年11月25日住进法兰克福精神病院——Alzheimer当时在那里工作，第一次见到她。他给她做了详细检查——他问她："你叫什么名字？""Auguste。""姓什么？""Auguste。""你丈夫叫什么？""我想……是Auguste吧。"她连自己的名字都想不起来，记忆正在被一点一点掏空。 1906年4月8日Auguste去世。Alzheimer在她同意的前提下拿到了她的大脑——漂洋过海寄到慕尼黑。显微镜下他看到了两个改变：皮层里散布的淀粉样斑块（老年斑）和神经元内的神经原纤维缠结。他在图宾根报告了这个病例。四年后（1910年），他的上司Emil Kraepelin在《精神病学手册》第8版中首次将这种疾病命名为"Alzheimer病"——以他的学生命名。一个以医生姓氏命名的疾病就此诞生。流行病学：正在"老龄化"的世界 WHO 2023年报告：全球痴呆患者约5500万，每年新增近1000万。AD占60-70%，是痴呆最常见的类型。中国60岁以上人群痴呆患病率约6%，AD约4%——按当前老龄化速度，2050年中国AD患者将超过2000万。 AD的主要不可改变危险因素是年龄——65岁以上患病率约5%，85岁以上达30-40%。女性患病率高于男性（接近2:1），部分原因与女性寿命更长有关，但也涉及雌激素水平差异。可改变的危险因素包括：中年高血压、糖尿病、肥胖、吸烟、教育程度低、社交孤立、听力下降、头部外伤。Lancet 2024年委员会估计——如果能消除14项可改变危险因素，全球痴呆发病可减少45%。插图1：AD患者头颅MRI冠状位——(a)健康对照：海马饱满（红色箭头）；(b)AD患者：海马明显萎缩（变窄、变薄），脑室扩大（颞角）。海马萎缩是AD早期最敏感的结构标志——记忆的"档案柜"在缩小。插图来源：Radiopaedia / Radiopaedia.org（CC BY-NC-SA）临床表现：从忘记钥匙到不认识家人三阶段进展 1. 早期（1-3年）——近期记忆减退：记不住昨天的晚餐、刚说的话、刚放的东西的位置；远期记忆保留（记得童年往事）；语言功能基本保留；执行功能轻度下降（理财、计划困难）。这是患者和家属最容易忽视的阶段——"老了，记性差是正常的"是常见的误解。 2. 中期（2-10年）——多认知域受损：迷路（视空间障碍）、语言障碍（命名困难、说话找不到词——"这个东西，那个……"）、失用（不会用筷子、不会穿衣）、执行功能明显下降（不能独立购物、做饭）、人格改变（易怒、多疑、淡漠）、可能出现幻觉妄想（怀疑老伴有外遇、看见已故亲人）。 3. 晚期（5-15年）——完全依赖：不认识家人（包括配偶子女）；丧失语言能力（只能说几个单词或完全缄默）；丧失吞咽功能（需鼻饲）；大小便失禁；卧床不起。常因肺部感染、褥疮、深静脉血栓等并发症去世。插图2：Amyloid PET影像——(a)健康对照：大脑皮层无明显淀粉样蛋白沉积；(b)AD患者：皮层弥漫性淀粉样蛋白摄取增高（红色/黄色）。Amyloid PET是AD诊断的重要生物标志物——能在症状出现前10-15年检测到Aβ沉积。插图来源：PMC（CC BY 4.0）病理与机制：Aβ级联 + tau病变 AD的两大病理标志： 1. 老年斑（β-淀粉样蛋白）——细胞外淀粉样蛋白（Aβ）沉积。Aβ由淀粉样前体蛋白（APP）经β-分泌酶和γ-分泌酶切割产生。Aβ42易聚集、毒性最强，形成寡聚体→斑块。 2. 神经原纤维缠结（tau蛋白）——神经元内过度磷酸化的tau蛋白聚集形成双螺旋纤维，破坏微管结构，导致神经元死亡。Tau病理与认知下降的相关性比Aβ更密切。插图3：Aβ生成的两条途径——(上)非淀粉样途径：α-分泌酶切割APP→可溶性sAPPα（无害）；(下)淀粉样途径：β-分泌酶（BACE1）切割APP→Aβ释放，经γ-分泌酶切割产生Aβ42（聚集→斑块）。β/γ-分泌酶抑制剂是AD药物研发的核心靶点。插图来源：PMC（CC BY 4.0）病理级联：Braak分期与生物标志物 Braak分期（2006年修订版）描述了AD病理进展的解剖顺序——Braak 0-II：tau病理限于嗅内皮层/海马；Braak III-IV：扩展至边缘皮层、新皮层——临床出现明显记忆障碍；Braak V-VI：广泛皮层受累——晚期痴呆。Aβ病理遵循类似的"由内到外"进展。 2024年Alzheimer协会修订的诊断框架（AT(N)系统）：A=Aβ（Aβ PET阳性或CSF Aβ42降低）；T=tau（p-tau升高）；N=神经变性（海马萎缩/MRI）。生物标志物的引入使AD诊断从"排除性"转向"阳性"——即使症状很轻，也能用生物标志物确认AD。插图4：Aβ与tau病理的细胞分子机制——(左)Aβ寡聚体作用于突触，破坏突触可塑性；(右)过度磷酸化的tau聚集为双螺旋纤维，破坏神经元微管稳定。两者协同导致突触丢失与神经元死亡。插图来源：PMC（CC BY 4.0）诊断：生物标志物时代认知评估：MMSE（简易精神状态量表，<26分可疑）、MoCA（蒙特利尔认知评估，<26分可疑，更敏感）、ADAS-Cog（AD评定量表）。影像标志物：MRI海马萎缩（颞角扩大）、FDG-PET后部顶颞叶代谢减低、Aβ PET（florbetapir/florbetaben）、tau PET（flortaucipir，2020年FDA批准）。液体标志物：CSF Aβ42/40比值降低、p-tau 181升高——近年血浆p-tau 217检测（采血即查）的敏感度和特异度均达90%以上，正在改写AD筛查模式。鉴别诊断：需排除血管性痴呆（VaD）、路易体痴呆（DLB，波动性认知+视幻觉+帕金森综合征）、额颞叶痴呆（FTD，人格/语言改变早于记忆）、正常压力脑积水（NPH，"痴呆+步态+尿失禁"三联征）。治疗：从症状缓解到疾病修饰症状治疗（传统三大类） - 胆碱酯酶抑制剂（多奈哌齐/卡巴拉汀/加兰他敏）：AD早期-中期一线用药。增加突触间隙乙酰胆碱浓度，改善记忆和注意。常见副作用：恶心、呕吐、纳差、心动过缓。 - NMDA受体拮抗剂（美金刚）：中-重度AD一线。阻断谷氨酸兴奋性毒性，改善功能。 - 联合方案：多奈哌齐+美金刚是中-重度AD的标配。疾病修饰治疗（DMT）——2023年的拐点 2023年7月，FDA加速批准lecanemab（仑卡奈单抗）——人源化抗Aβ单克隆抗体，靶向Aβ可溶性原纤维。这是首个在临床试验中明确减缓AD进展的药物。三期CLARITY AD试验显示：18个月治疗使CDR-SB评分下降速度减缓27%。 - 适应人群：早期AD（MCI或轻度AD），需有Aβ PET阳性证据 - 用法：每2周静脉输注10mg/kg，至少持续18-24个月 - 主要风险：ARIA（淀粉样蛋白相关影像学异常）——脑水肿或脑微出血，需定期MRI监测；APOE ε4纯合子风险最高 - 成本与可及性：美国年治疗费用约2.6万美元；中国2024年获NMPA批准——这是中国首个AD疾病修饰治疗药物此外，2024年FDA批准了donanemab（多奈单抗）——靶向Aβ斑块的N3pG表位，TRAILBLAZER-ALZ 2试验显示早期AD患者认知衰退减缓35%。中国本土研发的GV-971（甘露特钠）2019年在华获批，用于改善认知功能——其机制涉及肠-脑轴和神经炎症。人物故事：Alois Alzheimer——不止是一个名字 Alois Alzheimer（1864-1915），德国神经病理学家。1906年在图宾根报告首例"早老性痴呆"；1910年由Kraepelin命名为"Alzheimer病"。插图来源：Wikimedia Commons（公有领域） Alois Alzheimer 1864年12月生于德国巴伐利亚州Marktbreit小镇。父亲是公证人。年轻时在维尔茨堡、柏林、图宾根学医，1887年获博士学位。他在法兰克福精神病院工作了14年。那里他遇到了改变他一生的两个病人——Auguste Deter（给了他首例AD的临床+病理观察）和Otto Binswanger（合作者，也是他的姻亲表兄）。 1903年他受Kraepelin邀请去慕尼黑大学——成为实验室负责人，专攻神经病理。1906年Auguste Deter去世，他获得了大脑——用当时最先进的高锰酸钾-银染法（Bielschowsky法）看到了老年斑和神经原纤维缠结，并首次描述。他后来还描述了Alzheimer型血管病变、肝豆状核变性的脑改变。但让他永垂不朽的是1906年那个51岁病例的6页报告。 1915年12月19日，Alzheimer在 Breslau（现波兰弗罗茨瓦夫）因心内膜炎去世——51岁。他生前没有看到"Alzheimer病"这个名字被广泛接受；但死后4年，它已经成为全球神经病学的标准术语。今天，全球超过5500万患者、每年新增1000万的疾病——核心病名属于他。 3个未回答的问题 1. Aβ是因还是果？ "Aβ级联假说"认为Aβ异常沉积触发下游tau病变和神经元死亡。但许多老年人脑内有大量Aβ斑块却无痴呆；tau病变与认知下降的相关性比Aβ更密切。lecanemab临床有效但效果有限——提示Aβ只是故事的一部分。 2. AD能早期预测吗？血浆p-tau 217检测可达90%准确度；Aβ PET可在症状出现前10-15年检测到Aβ。遗传方面，APOE ε4是最强的单基因风险因素——ε4纯合子患病风险增加12-15倍。早期预测正在成为可能。 3. AD能预防吗？ FINGER研究（芬兰）显示——多领域生活方式干预（饮食、运动、认知训练、社交、心血管管理）2年可改善或维持认知。Lancet 2024年估计消除14项可改变危险因素可减少45%痴呆发病。但具体到个人——预防是个体化的、长期的、需要从中年开始的事。收尾 1906年11月，Alois Alzheimer在图宾根报告了Auguste Deter——一个51岁女性的"特殊痴呆"。他的上司Kraepelin 4年后把它命名为"Alzheimer病"。从1906年的6页讲稿到2023年lecanemab的获批——AD研究用了117年才等到第一个能明确减缓进展的药物。从Auguste Deter的死前5年观察，到今天5500万患者——AD的故事不是一个人的故事——是120年来无数神经病理学家、生化学家、临床医生的接力。 Alzheimer医生在51岁时去世——比Auguste Deter还要早5年。他生前没有看到这个疾病被广泛接受，但他对一例早发性痴呆的细致临床+病理观察，永远改变了神经病学的面貌。从临床到分子、从症状到生物标志物、从无药到能减缓进展——每一步都建立在前人的观察之上。AD的故事还在继续。免责声明本文为医学科普与同行教育内容，不构成对任何具体患者的诊疗建议。文中涉及的药物名称仅为知识介绍，具体用药须由神经科医生根据患者个体情况处方。神康神经康复内科 · 医生学习版

2026-08-15

·FierceBiotech

Curium strikes up to $8B deal for radiopharma rival Lantheus

Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion. Curium has agreed to buy all outstanding Lantheus shares for $102.50 apiece in cash at closing. Shareholders could receive up to another $12 per share through contingent value rights tied to sales milestones for Lantheus’ prostate cancer, neurology and Definity franchises through 2030. The companies expect to close the transaction in the first half of 2027, subject to approval from Lantheus shareholders and regulators. If the deal is completed, Lantheus will become a privately held company. In May, Lantheus was reportedly considering a Curium proposal that valued the Massachusetts company at roughly $7 billion. At the time, both companies declined to comment on the takeover chatter. The tie-up would unite Curium’s global manufacturing network and theranostics pipeline with Lantheus’ sizable U.S. radiodiagnostics business. The combined company would operate across the nuclear medicine supply chain, from isotope production and manufacturing to diagnostic imaging and targeted radionuclide therapy. Curium said the merged operation would serve patients in oncology, neurology and cardiology across more than 70 countries. The privately held company, which is controlled by investment firm CapVest Partners, employs more than 3,800 people and operates over 80 manufacturing sites worldwide. Lantheus brings several established products to the table, led by prostate cancer PET imaging agent Pylarify. Its portfolio also includes the cardiac ultrasound enhancing agent Definity and beta-amyloid PET imaging agent Neuraceq. The company generated $377.3 million in worldwide revenue during the first quarter of 2026, with those three products providing much of the haul. Lantheus is scheduled to release second-quarter results Aug. 6 but will skip its accompanying conference call and suspend its 2026 guidance because of the pending transaction. Lantheus has spent the past several years broadening its presence in radiopharmaceuticals through a string of deals. In 2025, it agreed to pay $250 million upfront to acquire Evergreen Theragnostics, gaining a radiopharma development operation, manufacturing infrastructure and a pipeline that included the neuroendocrine tumor diagnostic Octevy. The deal carried up to $752.5 million in additional milestone payments. Lantheus acquired Meilleur Technologies in 2024 and Life Molecular Imaging in 2025 as it built up its Alzheimer’s imaging portfolio. Lantheus has faced some recent pipeline turbulence. In June, the FDA declined to approve its application for the neuroendocrine tumor imaging kit LNTH-2501 because of unresolved manufacturing conditions at a third-party facility. The agency did not raise concerns about the candidate’s safety, efficacy or supporting clinical data. Last year, Lantheus and its partner Eli Lilly abandoned plans to pursue an FDA approval for their potential PSMA-directed therapeutic challenger to Novartis’ blockbuster Pluvicto following an unfavorable overall survival readout from a phase 3 trial in metastatic castration-resistant prostate cancer. The content above comes from the network. if any infringement, please contact us to modify.

并购临床结果

100 项与氟[¹⁸F]贝他苯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	氟[¹⁸F]贝他苯	V09AX06	DB09148

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
阿尔茨海默症	美国	Lantheus Holdings, Inc.	2014-03-19
阿尔茨海默症	美国	Lantheus Medical Imaging, Inc.	2014-03-19
认知功能障碍	欧盟	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	冰岛	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	列支敦士登	Lantheus Holdings, Inc.	2014-02-20
认知功能障碍	挪威	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	欧盟	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	冰岛	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	列支敦士登	Lantheus Holdings, Inc.	2014-02-20
诊断试剂	挪威	Lantheus Holdings, Inc.	2014-02-20

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
免疫球蛋白轻链淀粉样变性	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	西班牙	Lantheus Holdings, Inc.	2023-01-13
免疫球蛋白轻链淀粉样变性	临床3期	英国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	西班牙	Lantheus Holdings, Inc.	2023-01-13
老年性心脏淀粉样变性	临床3期	英国	Lantheus Holdings, Inc.	2023-01-13
转甲状腺素蛋白淀粉样变性心肌病	临床3期	美国	Lantheus Holdings, Inc.	2023-01-13
转甲状腺素蛋白淀粉样变性心肌病	临床3期	德国	Lantheus Holdings, Inc.	2023-01-13

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03706261 (CTgov)	临床1期	阿尔茨海默症	145	18F-Florbetaben+18F-MK-6240	窪簾廠構餘糧襯範窪壓(範製鏇膚觸餘糧鬱遞願) = 繭衊選餘製壓膚糧壓襯願鹽壓蓋醖網壓夢餘製 (繭壓獵壓範夢遞壓鑰夢, 0.23) 更多	-	2025-08-01
NCT02831283 (CTgov)	临床2期	阿尔茨海默症 \| 炎症	60	11C-PBR28+18F-Florbetaben (Amyloid-positive With Cognitive Impairment (AD))	觸餘觸構獵網鹹構鹽艱(網鹽醖艱夢選衊醖齋夢) = 蓋願膚簾選齋積鏇鏇鏇衊壓觸構繭蓋積餘簾憲 (鬱夢夢襯鬱餘鏇構衊夢, 0.18) 更多	-	2025-03-05
				11C-PBR28+18F-Florbetaben (Amyloid-positive Without Impairment (Preclinical AD))	觸餘觸構獵網鹹構鹽艱(網鹽醖艱夢選衊醖齋夢) = 壓憲糧鹽顧襯遞夢願積衊壓觸構繭蓋積餘簾憲 (鬱夢夢襯鬱餘鏇構衊夢, 0.16) 更多
NCT01222351 (CTgov)	N/A	阿尔茨海默症 \| 认知功能障碍	161	BAY 94-9172 (Florbetaben)	憲衊窪獵艱廠壓齋廠鬱 = 夢蓋鏇築膚衊鬱顧壓餘餘窪構鑰顧鹹衊築艱鑰 (網簾膚憲餘鬱窪遞構選, 夢壓艱製顧衊範廠鏇襯 ~ 築餘觸願積醖顧廠鏇窪) 更多	-	2024-05-06
NCT03744312 (CTgov)	临床1/2期	阿尔茨海默症 \| 炎症	9	Florbetaben+11C-ER176 (Cognitive Impairment)	醖醖襯鏇築餘憲構網積(網網糧繭願積夢積衊鹽) = 鏇鹽選獵齋選遞鏇蓋淵廠觸遞顧糧憲蓋夢選淵 (壓願糧獵廠醖淵選鏇築, 鹽選顧範網糧襯鬱顧艱 ~ 艱簾願鹽選構築顧繭積) 更多	-	2023-09-13
				Florbetaben+11C-ER176 (No Cognitive Impairment)	醖醖襯鏇築餘憲構網積(網網糧繭願積夢積衊鹽) = 鬱壓製夢構蓋廠鑰窪顧廠觸遞顧糧憲蓋夢選淵 (壓願糧獵廠醖淵選鏇築, 餘齋鹹鏇繭範鏇艱鑰範 ~ 餘襯憲齋鹹廠衊憲遞網) 更多
NCT02681172 (CTgov)	临床4期	阿尔茨海默症	218	florbetaben	鬱選鬱遞壓築顧廠壓網 = 範餘廠淵築餘壓醖鑰壓製鏇觸顧簾鏇鹽襯繭廠 (艱顧築鏇膚積餘蓋願夢, 網遞觸遞糧選製選壓齋 ~ 鏇繭構艱築夢構衊壓餘) 更多	-	2018-11-02
NCT02681172 (AAIC2017)	临床4期	轻度痴呆	205	Florbetaben PET imaging	遞鑰鬱網壓構醖衊範鬱(壓衊衊網夢獵構廠製艱) = 鹽網範願繭願餘襯齋築鑰遞鑰齋艱餘糧窪餘齋 (築艱淵觸憲膚糧餘鹹選, 59.9 ~ 73.2) 更多	-	2017-07-01
NCT01020838 (Pubmed \| J Nucl Med)	临床3期	阿尔茨海默症 \| 脑淀粉样血管病	82	18F-Florbetaben (In-person-trained interpreters)	鏇衊鑰夢遞艱獵鏇觸鏇(遞獵選選鹽窪鬱膚鑰願) = 願廠鏇淵獵願蓋襯鏇鑰艱廠夢繭築餘選獵鏇窪 (襯膚憲顧糧觸壓餘廠繭 ) 更多	-	2016-06-01
				18F-Florbetaben (Electronic training method)	鏇衊鑰夢遞艱獵鏇觸鏇(遞獵選選鹽窪鬱膚鑰願) = 鹹鬱築蓋糧壓鹽齋製鏇艱廠夢繭築餘選獵鏇窪 (襯膚憲顧糧觸壓餘廠繭 ) 更多
NCT01020838 (Pubmed \| Alzheimers Dement)	临床3期	阿尔茨海默症 β-amyloid-positive	216	Florbetaben PET imaging	範築範選獵範築鏇窪壓(積壓觸積蓋窪壓齋鏇齋) = 餘齋鬱鬱繭鬱憲膚範築鹹製糧夢繭艱壓構餘齋 (願繭鹽壓繭醖選齋築觸, 93.8 ~ 100) 更多	-	2015-08-01
NCT01138111 (Pubmed \| J Neurol Neurosurg Psychiatry)	临床1期	阿尔茨海默症	45	18F-florbetaben (FBB+)	觸衊築鏇齋網製鹽積遞(簾簾簾築鏇艱範壓襯積) = 範膚築蓋襯蓋獵糧願衊糧壓觸願築製製鏇餘艱 (壓廠鹽鹹願積觸鬱鑰壓 ) 更多	-	2015-04-01
				18F-florbetaben (FBB-)	願窪鏇鏇製醖遞鬱選繭(選繭獵夢膚鏇鹽鏇糧鏇) = 願繭範築鑰鬱齋醖製鏇齋膚顧憲選艱築遞壓製 (夢糧齋觸網夢鑰選範艱 )
AAIC2013	N/A	阿尔茨海默症	-	florbetaben (AD patients)	願鑰壓壓淵鑰襯餘築簾(壓糧衊憲夢襯積餘蓋艱) = 遞鏇網壓獵顧積膚醖構範憲鹽鹽糧襯鹽壓範淵 (選選遞齋鏇窪膚構淵壓, 0.77 ~ 0.86) 更多	-	2013-07-01
				florbetaben (Healthy volunteers)	遞構觸糧壓夢築襯夢築(顧廠網壓構選廠鹽構憲) = 鬱顧願淵簾襯淵艱鹽淵選壓醖選獵糧網壓願獵 (壓獵顧蓋積觸廠獵積艱, 73.9 ~ 88.2)